Author Archive: Tracy Cooley

Tracy was the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues.

Latest Posts

AP: Groups Claim Insurance Discrimination


In this August 18 article, Ricardo Alonso-Zaldivar highlights assertions by patient groups that new insurance barriers are discriminatory against sick people, particularly patients with chronic conditions. More than 300 patient advocacy groups – including the AIDS Institute, the American Lung Association, Easter Seals, the Epilepsy Foundation, the Leukemia & Lymphoma Society, the National Alliance on Mental Illness, the National Kidney Foundation and United Cerebral Palsy – recently wrote to Health and Human Services Secretary Sylvia Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Docs to FDA: Biosimilars should have different names than branded drugs


Yesterday, Fierce Biotech highlighted a letter written by more than 10 medical associations and 20 individual specialists to FDA Commissioner Margaret Hamburg saying that biosimilars “must have distinguishable nonproprietary names. The FDA drafted a set of rules for biosimilars in 2012, sparking a debate on whether those drugs should carry the same generic names as the originator products. Now, some doctors are weighing in on the issue, urging the FDA to require biosimilars to have distinguishable names. The physicians argued that using different Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

New study shows hepatitis C burden may ease in future


Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis C will shrink in the coming decades thanks to new medicines and increased screening regimens. Currently, approximately one in 100 people are infected with the virus, and researchers expect that number to drop to about one in 1,500 people by 2036 if patients have timely and affordable treatment. “We were pleasantly surprised that in the next 22 years we could Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

New York Times Building

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the attention the cost has received to date, those attacking the drug are “looking at the costs of Sovaldi in the wrong way.” Sanger-Katz acknowledges that these one-time treatments can be a ‘shock to the system,’ but notes the value far outweighs the expense since it cures the disease in the majority of patients, preventing further costly treatments and care. Sanger-Katz Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Treating Hepatitis C: Too Costly Not to Act


Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act – by California Healthcare Institute’s Todd Gillenwater on the value of breakthrough Hepatitis C medicines that cure the disease in the majority of patients. As Gillenwater asserts, “New hepatitis C drugs mark a paradigm shift – from a model of somewhat iffy but costly chronic care to a model of short-term curative treatment with equal or slightly lower costs paid Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,